Jane Street
NKTR icon

Jane Street’s Nektar Therapeutics NKTR Stock Holding History

Jane Street’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.57M Sell
22,500
-20,400
-48% -$1.49M ﹤0.01% 5604
2026
Q1 		$3.09M Buy
42,900
+36,400
+560% +$2.07M ﹤0.01% 4292
2025
Q4 		$275K Sell
6,500
-13,321
-67% -$746K ﹤0.01% 9037
2025
Q3 		$1.13M Buy
+19,821
New +$656K ﹤0.01% 6057
2023
Q4 		– Sell
-1,047
Closed -$9.35K – 9604
2023
Q3 		$9.35K Buy
+1,047
New +$10.1K ﹤0.01% 8391
2022
Q4 		– Sell
-8,333
Closed -$400K – 9794
2022
Q3 		$400K Sell
8,333
-2,334
-22% -$139K ﹤0.01% 7097
2022
Q2 		$608K Sell
10,667
-16,306
-60% -$1.03M ﹤0.01% 6385
2022
Q1 		$2.18M Sell
26,973
-1,294
-5% -$192K ﹤0.01% 4586
2021
Q4 		$5.73M Buy
28,267
+6,580
+30% +$1.43M ﹤0.01% 2647
2021
Q3 		$5.84M Buy
21,687
+7,920
+58% +$1.9M ﹤0.01% 2499
2021
Q2 		$3.54M Buy
13,767
+11,260
+449% +$3.12M ﹤0.01% 3255
2021
Q1 		$752K Sell
2,507
-666
-21% -$207K ﹤0.01% 6019
2020
Q4 		$809K Sell
3,173
-3,240
-51% -$837K ﹤0.01% 5008
2020
Q3 		$1.6M Sell
6,413
-1,247
-16% -$392K ﹤0.01% 3371
2020
Q2 		$2.66M Buy
+7,660
New +$2.39M ﹤0.01% 2670
2018
Q3 		– Sell
-3,520
Closed -$2.58M – 5508
2018
Q2 		$2.58M Buy
3,520
+3,093
+724% +$3.57M 0.01% 1650
2018
Q1 		$680K Buy
427
+127
+42% +$164K ﹤0.01% 3126
2017
Q4 		$269K Buy
+300
New +$177K ﹤0.01% 3888
2017
Q2 		– Sell
-920
Closed -$324K – 4692
2017
Q1 		$324K Buy
+920
New +$207K ﹤0.01% 3335
2016
Q1 		– Sell
-693
Closed -$175K – 4469
2015
Q4 		$175K Buy
+693
New +$143K ﹤0.01% 3662
2015
Q3 		– Sell
-680
Closed -$128K – 3967
2015
Q2 		$128K Buy
+680
New +$117K ﹤0.01% 3379

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street's NKTR Position: Q2 2026 in Review

Jane Street reduced its Nektar Therapeutics (NKTR) stake by 93% in Q2 2026, selling an estimated $7.63M and leaving 8,327 shares worth $581K. The position accounts for ﹤0.01% of the portfolio, ranked #7671.

Jane Street first reported a position in NKTR in Q2 2013 and has held it in 34 quarters since. The position peaked at $16.4M in Q2 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Jane Street held 8,327 shares of Nektar Therapeutics worth $581K as of Q2 2026.
  • Jane Street sold 104,325 Nektar Therapeutics shares in Q2 2026, an estimated $7.63M.
  • Nektar Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #7671 holding.
  • Jane Street first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 34 quarters since.
  • Jane Street's Nektar Therapeutics position peaked at $16.4M in Q2 2018.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.